Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Net Income (2016 - 2025)

Voyager Therapeutics' Net Income history spans 11 years, with the latest figure at -$27.4 million for Q4 2025.

  • For Q4 2025, Net Income rose 20.47% year-over-year to -$27.4 million; the TTM value through Dec 2025 reached -$119.7 million, down 84.18%, while the annual FY2025 figure was -$119.7 million, 84.18% down from the prior year.
  • Net Income for Q4 2025 was -$27.4 million at Voyager Therapeutics, up from -$27.9 million in the prior quarter.
  • Across five years, Net Income topped out at $124.0 million in Q1 2023 and bottomed at -$34.5 million in Q4 2024.
  • The 5-year median for Net Income is -$22.9 million (2022), against an average of -$8.6 million.
  • The largest annual shift saw Net Income tumbled 566.69% in 2022 before it skyrocketed 681.85% in 2023.
  • A 5-year view of Net Income shows it stood at $5.1 million in 2021, then crashed by 566.69% to -$23.6 million in 2022, then skyrocketed by 338.86% to $56.4 million in 2023, then plummeted by 161.15% to -$34.5 million in 2024, then increased by 20.47% to -$27.4 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Net Income are -$27.4 million (Q4 2025), -$27.9 million (Q3 2025), and -$33.4 million (Q2 2025).